基于生物信息学研究分析弥漫大B细胞淋巴瘤的潜在靶标与挖掘治疗药物  

Analysis of Potential Targets and Therapeutic Drugs for Diffuse Large B-cell Lymphoma Based on Bioinformatics

作　　者：梅汉玮 何国平 赵轩竹 王华庆 Mei Hanwei;He Guoping;Zhao Xuanzhu;Wang Huaqing(College of Integrated Chinese and Western Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;Cancer Diagnosis and Treatment Center of Tianjin People’s Hospital,Tianjin 300122,China;Institute of Translational Medicine,People’s Hospital of Nankai University,Tianjin 300122,China)

机构地区：[1]天津中医药大学中西医结合学院,天津301617 [2]天津市人民医院肿瘤诊疗中心,天津300122 [3]南开大学人民医院转化医学研究院,天津300122

出　　处：《黑龙江科学》2023年第8期103-105,共3页Heilongjiang Science

基　　金：天津市医学重点学科(专科)建设项目(TJYXZDXK-053B);国家自然科学基金(82070206)。

摘　　要：为通过生信分析筛选参与弥漫大B细胞淋巴瘤发生发展的关键基因,预测治疗性小分子化学药物,从GEO和ICGC数据库中下载弥漫大B细胞淋巴瘤芯片和相关基因谱,使用R软件筛选共表达差异基因,对与芯片预后风险因素一致的基因取交集。通过STRING 11.0数据库及Cytoscape 3.7.2软件分析DEGs中的关键Top10基因,获得差异基因,将关键基因导入医学本体信息检索数据库,筛选治疗淋巴瘤细胞的化学药物Palomid-529,利用R软件与Sanger Box软件,分别验证关键基因在弥漫大B细胞淋巴瘤数据集中的预后生存情况。纳入VSIG4、CCRL2、SIGLEC1、CD163作为靶标分子对接,使用Autodock分子对接软件,分析治疗药物与关键基因转录的小分子-蛋白结合能情况。结果表明,Palomid-529能与VSIG4、CCRL2、SIGLEC1、CD163靶点对接,结合能量值分别为-6.12 KJ/mol、-6.79 KJ/mol、-5.17 KJ/mol、-8.99 KJ/mol,说明VSIG4、CCRL2、SIGLEC1、CD163靶点有可能作为DLBCL的诊治及预后指标,而Palomid-529有可能作为治疗此疾病的一个小分子药物,可为相关化学药物的开发提供靶标及研究思路。In order to screen key genes involved in the development of diffuse large B-cell lymphoma,and predict therapeutic small molecule chemicals by bioinformatics analysis,diffuse large B-cell lymphoma chips and related gene profiles are downloaded from GEO and ICGC databases,R software is used to screen coexpression differential genes,and the intersection of genes consistent with the prognostic risk factors of diffuse large B-cell lymphoma is selected.Through STRING 11.0 database and Cytoscape 3.7.2 software,the top 10 key genes in DEGs are analyzed to obtain the differential genes,the key genes are imported into the medical ontology information retrieval database,chemical drug Palomid-529 used to treat lymphoma cells is screened,and R software and Sanger Box software are used to verify the prognostic survival of key genes in diffuse large B-cell lymphoma data sets,respectively.VSIG4,CCRL2,SIGLEC1 and CD163 are included as target molecules for docking.Autodock molecular docking software is used to analyze the small molecule-protein binding energy of therapeutics and key gene transcription.The results show that Palomid-529 can interconnect with VSIG4,CCRL2,SIGLEC1 and CD163,and the binding energy values are-6.12 KJ/mol,-6.79 KJ/mol,-5.17 KJ/mol and-8.99 KJ/mol,respectively.This indicates that VSIG4,CCRL2,SIGLEC1 and CD163 targets may be used as diagnosis,treatment and prognostic indicators of DLBCL.Palomid-529 may be a small molecule drug for the treatment of this disease,providing targets and research ideas for the development of related chemical drugs.

关 键 词：弥漫大B细胞淋巴瘤 生物信息学分析 关键基因 治疗 化学药物 

分 类 号：R733.1[医药卫生—肿瘤]